NasdaqCM - Nasdaq Real Time Price USD
Immix Biopharma, Inc. (IMMX)
1.7100
+0.0600
+(3.64%)
At close: April 22 at 4:00:01 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. | Co-Founder, CEO & Chairman | 669k | -- | 1973 |
| Mr. Gabriel Morris B.A. | CFO & Director | 669k | -- | 1987 |
| Dr. Graham Ross FFPM, M.D. | Chief Medical Officer & Head of Clinical Development | 104.42k | -- | 1960 |
| Mr. Sean Senn J.D., M.B.A., M.Sc., MBA, MSc | Co-Founder | -- | -- | -- |
| Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. | Scientific Co-Founder | -- | -- | 1947 |
| Mr. Nandan Oza B.S. | Head of Chemistry, Manufacturing & Control | -- | -- | 1962 |
| Dr. David Marks MBBS, Ph.D. | Chief Medical Officer of Cell Therapy | -- | -- | -- |
| Mr. Gerhard Bauer | Head of Cell Therapy Manufacturing | -- | -- | -- |
Immix Biopharma, Inc.
11400 West Olympic Boulevard
Suite 200
Los Angeles, CA 90064
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 18
Description
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Corporate Governance
Immix Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 7, 2025 at 8:00 PM UTC - May 12, 2025 at 8:00 PM UTC
Immix Biopharma, Inc. Earnings Date
Recent Events
Related Tickers
KTTA Pasithea Therapeutics Corp.
1.5400
+7.69%
OLMA Olema Pharmaceuticals, Inc.
4.9600
+4.42%
ENSC Ensysce Biosciences, Inc.
1.8700
+12.65%
A71.F Ascendis Pharma A/S
142.00
+1.43%
LTI0.F Aptose Biosciences Inc. R
2.0200
+1.00%
IVBXF Innovent Biologics, Inc.
5.98
0.00%
APTOF Aptose Biosciences Inc.
2.3100
-6.48%
BINV.ST BioInvent International AB (publ)
29.15
+3.37%
CLVLY Clinuvel Pharmaceuticals Limited
7.10
0.00%
PDSB PDS Biotechnology Corporation
1.1500
+6.48%